Gilead Sciences, Inc. (GILD)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
65.11+0.09 (+0.14%)
At close: 4:00PM EDT
| Previous close | 65.02 |
| Open | 64.82 |
| Bid | 65.00 x 2200 |
| Ask | 65.00 x 1000 |
| Day's range | 64.24 - 65.25 |
| 52-week range | 56.56 - 85.79 |
| Volume | 5,848,292 |
| Avg. volume | 8,383,722 |
| Market cap | 81.977B |
| Beta (5Y monthly) | 0.41 |
| PE ratio (TTM) | 664.39 |
| EPS (TTM) | 0.10 |
| Earnings date | 28 Apr 2021 - 03 May 2021 |
| Forward dividend & yield | 2.84 (4.36%) |
| Ex-dividend date | 12 Mar 2021 |
| 1y target est | 74.85 |
- Editor's pickYahoo Finance Video
Pfizer’s vaccine EUA expansion request is ‘extremely welcomed’: Doctor
Dr. Shereef Elnahal, University Hospital CEO, Former NJDOH Commissioner, joins Yahoo Finance’s Kristin Myers and Alexis Christoforous to discuss the latest on coronavirus vaccines.
- Yahoo Finance Video
Study shows wearables could detect COVID-19 earlier
Tejaswini Mishra, PhD, Research Scientist in the Department of Genetics at Stanford University School of Medicine, joins Yahoo Finance’s Alexis Christoforous to discuss the use of wearables to detect COVID-19.
- Zacks
Gilead (GILD) Gets Full Approval for Breast Cancer Drug Trodelvy
Gilead (GILD) obtains full approval for its breast cancer drug, Trodelvy, in the United States for metastatic triple-negative breast cancer.
© 2021 Verizon Media. All rights reserved.
